Epithalon vs Exenatide
Side-by-side comparison of key properties, dosing, and research.
- Summary
- Epithalon is a synthetic tetrapeptide developed from the pineal gland extract Epithalamin by Russian scientist Dr. Vladimir Khavinson. It is one of the most researched longevity peptides, known for activating telomerase and extending telomere length — the molecular hallmarks of cellular aging.
- Exenatide is a GLP-1 receptor agonist derived from the Gila monster lizard peptide exendin-4, with 53% homology to human GLP-1 and natural resistance to DPP-4 degradation. Available as twice-daily (Byetta) or once-weekly (Bydureon) formulation, it is also being studied for Parkinson's disease neuroprotection.
- Half-Life
- 2–4 hours
- ~2.4 hours (Byetta/twice-daily); Bydureon BCISE: weekly via microsphere release
- Admin Route
- SubQ, Sublingual
- SubQ
- Research
- —
- —
- Typical Dose
- 5–10 mg total per cycle
- 5 mcg, titrate to 10 mcg
- Frequency
- 0.5–1 mg daily
- Twice daily
- Key Benefits
- Activates telomerase enzyme, extending telomere length
- May slow cellular and biological aging
- Regulates melatonin production and circadian rhythms
- Improves sleep quality
- Powerful antioxidant properties
- May reduce incidence of age-related diseases
- Supports immune system function
- Studied for cancer prevention properties in animal models
- Blood glucose control in type 2 diabetes
- Weight loss (average 2–3 kg in clinical trials)
- Once-weekly extended-release formulation available
- Reduces appetite and food intake
- Possible neuroprotective in Parkinson's disease (Phase II trials)
- Reduces systemic inflammation
- May protect pancreatic beta cells
- Cardiovascular neutral or potentially protective
- Side Effects
- Injection site irritation (mild)
- Temporary sleep changes during cycle (usually improves)
- Rare: fatigue
- Nausea (most common, especially initially)
- Vomiting
- Diarrhea
- Headache
- +4 more
- Stacks With
- —
- —